CRISIL Limited (BOM:500092)
India
· Delayed Price · Currency is INR | Market Cap | 409.64B |
| Revenue (ttm) | 33.35B |
| Net Income (ttm) | 7.06B |
| Shares Out | n/a |
| EPS (ttm) | 96.57 |
| PE Ratio | 58.01 |
| Forward PE | 51.93 |
| Dividend | 57.00 (1.02%) |
| Ex-Dividend Date | May 7, 2025 |
| Volume | 5,965 |
| Average Volume | 4,132 |
| Open | 5,754.70 |
| Previous Close | 5,668.70 |
| Day's Range | 5,434.05 - 5,754.70 |
| 52-Week Range | 3,893.85 - 6,955.40 |
| Beta | n/a |
| RSI | 62.86 |
| Earnings Date | Jul 15, 2025 |
About CRISIL
CRISIL Limited, an analytical company, provides ratings, research, and risk and policy consulting services in India, Europe, North America, and internationally. It operates through two segment, Rating Services; and Research, Analytics and Solutions. The company offers credit ratings for corporates, banks, and bank loans; credit analysis services; grading services; and analytical services. It also provides research and risk solutions, industry reports, customized research assignments, subscription to data services, independent equity research, i... [Read more]
Financial Performance
In 2024, CRISIL's revenue was 32.60 billion, an increase of 3.83% compared to the previous year's 31.40 billion. Earnings were 6.84 billion, an increase of 3.89%.
Financial StatementsNews
CRISIL Q4 FY25 Results: Net profit rises 16% YoY to ₹159.8 crore, Margin expands to 28.5%
CRISIL Ltd has reported a strong set of numbers for the quarter ended March 31, 2025, with net profit rising 16% year-on-year to ₹159.8 crore, compared to ₹137.7 crore in the same period last year. Th...
Crisil shares drop over 8% as Q3 revenue declines
Crisil Limited, a subsidiary of S&P Global, faced a sharp decline in its stock price, dropping over 8% after reporting a slight dip in Q3 FY25 revenue. Despite strong profitability growth, investor se...
Crisil Q3 Results: Revenue down 0.5% to Rs 912.91 crore, Net Profit up 7.03% YoY
Crisil Limited, a subsidiary of S&P Global, has announced its audited financial results for Q3 FY25, reflecting a mixed performance across its revenue and profitability metrics. Key Financial Highligh...
Top gainers today: Piramal Pharma surges 5.85%, CRISIL rises 3.63%, Aditya Birla Capital gains 2.76%, AstraZeneca Pharma up 2.57%
At 12:53 PM, the stock market witnessed notable gains across several stocks. Here’s a look at the top performers: Piramal Pharma Limited (PPL Pharma): The stock climbed 5.85%, trading at ₹234.20. CRIS...
CRISIL invests Rs 33.25 Crore in online PSB Loans
CRISIL Limited has announced an investment of ₹33.25 crore to acquire a 4.08% post-money, fully diluted stake in Online PSB Loans Limited (OPL). This strategic move was approved during a board meeting...